McKesson Corporation (MCK)
McKesson Corporation (MCK) carries a ŷRobot AI score of 77 out of 100. The model's fair value estimate is $1,203.93, 9.2% above the last close of $1,102.81. The chart signal reads Sell.
| Metric | MCK |
|---|---|
| AI score | 77 / 100 |
| Chart signal | Sell |
| Fair value estimate | $1,203.93 |
| Upside to fair value | 9.2% |
| Previous close | $1,102.81 |
| P/E | 27.58 |
| Price / sales | 0.30 |
| Market cap | $124.35B |
| EPS | 38.77 |
| Revenue growth | 12.8% |
| 1-year price change | 27.0% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about MCK
Is MCK overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates McKesson Corporation (MCK) at $1203.93 against a last close of $1102.81, implying 9.2% upside to the model's estimate.
Is MCK's chart signal bullish or bearish?
The chart-signal model classifies MCK as Neutral as of Nov 13, 2026, with a signal score of -0.14 on a -1 to 1 scale.
What is MCK's ŷRobot AI score?
MCK scores 77 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is MCK stock expensive on P/E and P/S?
MCK trades at 27.6 times earnings and 0.3 times sales as of Nov 13, 2026.
What does MCK's seasonal forecast show?
ŷRobot's seasonal forecast curve for MCK reads +0.9% at 30 days, +6.4% at 90 days, and +27.0% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is MCK growing?
McKesson Corporation's revenue growth is +12.8% and free-cash-flow growth is +4.9% on the latest reported figures.
MCK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.